Glass House Brands (GLAS) Interest & Investment Income (2020 - 2025)
Glass House Brands' (GLAS) quarterly Interest & Investment Income came in at $576000.0 in Q4 2025, up 1694217.65% on a QoQ basis from -$34.0 in Q1 2024.
Glass House Brands (GLAS) Interest & Investment Income (2020 - 2025) Analysis & Trends
Glass House Brands (GLAS) has 6 years of Interest & Investment Income data on file, last reported at $576000.0 in Q4 2025.
- On a quarterly basis, Interest & Investment Income changed N/A year-over-year to $576000.0 in Q4 2025; TTM through Dec 2025 was $35.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $288000.0, changed N/A from the prior year.
- Interest & Investment Income for Q4 2025 stood at $576000.0, up from -$34.0 in the prior quarter.
- Over the last five years, Interest & Investment Income for GLAS reached as high as $35.1 million in Q4 2023 and fell as low as -$32.2 billion in Q2 2021.
- Historically, Interest & Investment Income has averaged -$3.8 billion across 5 years, with a median of -$35.0 in 2022.
- Across the five-year window, Interest & Investment Income plunged 49.8% in 2022 and jumped 61488.48% in 2023, its largest moves.
- Year by year, Interest & Investment Income stood at $113502.0 in 2021, then tumbled by 49.8% to $56975.0 in 2022, then soared by 61488.48% to $35.1 million in 2023, then plunged by 100.0% to -$34.0 in 2024, then jumped by 1694217.65% to $576000.0 in 2025.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $576000.0 in Q4 2025, -$34.0 in Q1 2024, and $35.1 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 576,000.00 |
| Mar 31, 2024 | -34.00 |
| Dec 31, 2023 | 35.09 Mn |
| Sep 30, 2023 | -34.00 |
| Jun 30, 2023 | -35.00 Mn |
| Mar 31, 2023 | -45,000.00 |
| Dec 31, 2022 | 56,975.00 |
| Sep 30, 2022 | -35.00 |
| Jun 30, 2022 | -472.00 Mn |
| Dec 31, 2021 | 113,502.00 |
| Sep 30, 2021 | -16.44 Bn |
| Jun 30, 2021 | -32.22 Bn |
| Mar 31, 2021 | -16,086.00 |
| Mar 31, 2020 | -98,341.00 |